SkyePharma

SkyePharma has appointed a new senior management team. Frank Condella has been named chief executive and Dr. Ken Cunningham has the newly created position of chief operating officer. Dr. Cunningham’s role will focus on ensuring the effective development of the company’s key products such as Flutiform.

Mr. Condella was previously president of the European operations of IVAX prior to its acquisition by Teva in 2005. He was closely involved with the respiratory franchise, one of its three core therapeutic areas, including managing the acquisition and integration of 3M’s branded respiratory business. Prior to joining IVAX in 2002, he held senior roles at Faulding Pharmaceuticals, Roche, and the Lederle unit of American Home Products.

Dr. Cunningham previously served as chief executive of the privately owned UK biotechnology company, Arakis. He has extensive experience in the development of respiratory products including the company’s lead product, a treatment for chronic obstructive pulmonary disease (COPD), which was licensed to Novartis in 2005. Prior to that he was vice president, International Affairs for Alza and vice president for clinical development for Sequus Pharmaceuticals. He also held a variety of clinical development and commercial strategy positions in Glaxo Wellcome and Warner-Lambert.